Nektar says Phase 2b REZOLVE-AA trial posts new 6-month off-treatment rezpegaldesleukin data in severe alopecia areata
Bitget2026/09/28 12:04- Nektar flagged new Phase 2b rezpegaldesleukin data in alopecia areata for future presentation at EADV 2026 in Vienna.
- The update will cover off-treatment follow-up, focusing on whether hair regrowth benefits persist once dosing stops.
- Separate EADV oral sessions will present atopic dermatitis maintenance findings, highlighting sustained symptom improvement with less frequent dosing.
- A late-breaking atopic dermatitis biomarker readout will detail early molecular changes consistent with drug activity.
- Nektar scheduled an Oct. 1, 2026 investor webcast to discuss the off-treatment alopecia areata results.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The British Pound rallies on a UK growth upgrade and gives more than half back
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Crypto prices
More
